title: Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
authors.affiliation: Lindner Center for Research & Education and Ohio Heart Health Center, Cincinnati, Ohio, USA. lindner@fuse.net
authors.forename: Dean J
authors.initials: DJ
authors.lastname: Kereiakes
authors.forename: A Michael
authors.initials: AM
authors.lastname: Lincoff
authors.forename: Keaven M
authors.initials: KM
authors.lastname: Anderson
authors.forename: Robert
authors.initials: R
authors.lastname: Achenbach
authors.forename: Kamlesh
authors.initials: K
authors.lastname: Patel
authors.forename: Elliot
authors.initials: E
authors.lastname: Barnathan
authors.forename: Robert M
authors.initials: RM
authors.lastname: Califf
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Topol
mesh_terms: D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000401:mortality / Q000628:therapy*; D004311:Double-Blind Method; D023381:Endpoint Determination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab